# Cancer Vaccine Launchpad \(CVLP\)

> Contract award record from UK public-sector procurement sources.

## Key facts

- Public buyer: [NHS England](/buyers/nhs-england/contract-awards)
- Contract winner: [UNIVERSITY OF SOUTHAMPTON](/contract-winners/university-of-southampton/public-sector-contract-awards)
- Award value: £1,397,592
- Tender value: £2,100,000
- Award date: 12 February 2024
- Published: 29 February 2024
- Contract start: 12 February 2024
- Contract end: 31 March 2026
- Stage: awarded
- Procurement category: services
- Notice ID: e717b134-b174-4a68-87d4-cf08d46566c6-728038
- OCID: ocds-b5fd17-0b123b14-75dc-4986-8da3-185d2b272310

## Description

The CVLP is a strategic priority and collaboration between NHS England, the Department of Health and Social Care \(DHSC\), the Office for Life Sciences \(OLS\), the National Institute of Health Research \(NIHR\) and Genomics England \(GEL\), with the aim to facilitate access to personalised cancer vaccine research trials\. The project was jointly announced in July 2023 with the Secretary of State and in partnership with the Prime Minister\. See link \(https://www\.gov\.uk/government/news/major-agreement-to-deliver-new-cancer-vaccine-trials\#:~:text=It will work by creating,become part of standard care\) Through the CVLP platform, cancer patients from across a network of up to 140 NHS cancer care providers will be asked to consent to be put forward for clinical trials\. Their surplus tissue samples, obtained through standard of care pathways, will be used to assess their eligibility\. The detail of any available trials will be shared with the participant and their treating clinical team to see if the patient wishes to take part, and if so, the patient will travel to the nearest trial site to access the clinical trial\. The CVLP is a feasibility study, facilitating access to personalised treatment cancer trials, for example cancer vaccines\. Patients will be identified across a network of up to 140 NHS cancer care providers\. Patients in the CVLP will be asked to consent for analysis of their tumour material, peripheral blood \(if trial requires\), and clinical data to establish whether they might be suitable for current or future cancer vaccine trials\. The detail of any available trials will be shared with the participant and their treating clinical team, to see if they would consider taking part in the trial\(s\) for which they are eligible\.

## Related contract awards

- [Finance Transformation & Enablement Project Support](/contracts/ocds-b5fd17-3607e706-33f0-41c5-b40f-d42e32d91957): NHS England
- [Frontline Digitisation - Support Offer, Tiger Teams](/contracts/ocds-b5fd17-e73c824e-1a70-4c61-8602-675ba87a9e1c): NHS England
- [Provision of Public Consultation and Engagement Services for the UISPC](/contracts/ocds-b5fd17-7e823320-0353-4ea3-8fc9-2da62d37a5e0): NHS England
- [MIGRATION ADVISORY COMMITTEE - literature review covering the causal link between migration and housing](/contracts/ocds-b5fd17-5cfe31c8-228f-43cc-b0f5-c92c27982d92): Home Office
- [MIGRATION ADVISORY COMMITTEE - the impact of migration on housing in the UK](/contracts/ocds-b5fd17-707ae579-f1a6-470f-a7d6-4ac855a42792): Home Office
- [DHSC: Statistical Advisor to Medicine Margin Survey](/contracts/ocds-b5fd17-c63fcdf3-df61-42e8-a6a9-0304bac7750e): Department of Health and Social Care

## Source

[View the original notice on Contracts Finder](https://www.contractsfinder.service.gov.uk/Notice/e717b134-b174-4a68-87d4-cf08d46566c6-728038)